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Intervention impact on depression product
appraisal and purchasing behavior by employers:
a randomized trial
Kathryn M Rost1*, Donna Marshall2 and Stanley Xu3,4
Abstract
Background: Employers can purchase high quality depression products that provide the type, intensity and
duration of depression care management shown to improve work outcomes sufficiently for many employers to
achieve a return on investment. The purpose of this randomized controlled trial was to test an intervention to
encourage employers to purchase a high quality depression product for their workforce.
Methods: Twenty nine organizations recruited senior health benefit professional members representing public or
private employers who had not yet purchased a depression product for all 100+ workers in their company. The
research team used randomization blocked by company size to assign eligible employers to: (1) a presentation
encouraging employers to purchase a high quality depression product accompanied by a scientifically-derived
return on investment estimate, or (2) a presentation encouraging employers to work with their most subscribed
health plan to improve depression treatment quality indicators. Two hundred ninety three employers (82.3% of 356)
completed baseline data immediately before learning that 140 employers had been randomized to the
evidence-based (EB) depression product presentation and 153 had been randomized to the usual care (UC)
depression treatment quality indicator presentation. Analysis of 250 (85.3% of 293) employers who completed
web-based interviews at 12 and/or 24 months was conducted to determine presentation impact on depression
product appraisal and purchasing behavior.
Results: The intervention had no impact on depression product appraisal in 232 subjects (F = 2.36, p = .07) or
depression product purchasing (chisquare = 1.82, p = .44) in 250 subjects. Depression product appraisal increased in
companies with greater health benefit generosity whose benefit professionals were male. Depression product
purchasing behavior increased in small companies compared to large companies, companies who knew a vendor
that sold depression products at baseline, companies with greater health benefit risk taking, and companies with
less politicalization of health care benefit decision making.
Conclusions: Policy makers need to build innovative bridges to the employer community to convince them to
purchase evidence-based benefits, even when benefits offer potential financial savings.
Trial registration: Clinical Trials Registration Number: NCT01013220.
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Background
Policy analysts have long recognized that five stakehol-
der groups (purchasers, plans, practices, providers, and
patients) have to actively support efforts to enhance pri-
mary care depression treatment for sustainable gains to
be realized [1]. Multiple randomized trials [2,3] and de-
monstration projects [4,5] have been conducted to build
this support among plans, practices, providers, and pa-
tients with comparatively little effort focused on pur-
chasers. Purchaser support is vital because models that
improve outcomes [2,3] also increase the direct costs of
care [6], at least for the first year a depressed individual
participates [7].
In the U.S., employers represent a substantial seg-
ment of purchasers, offering health insurance coverage
to 88.8% of individuals in the workforce [8]. In addition,
employers have ‘a skin in the game’. Studies demonstrate
that 7.6% of U.S. employees suffer a major depressive
episode each year [9] which substantially reduces their
capacity to work as evidenced by increased absenteeism
[10] and reduced productivity at work [10,11]. Random-
ized trials demonstrate that interventions which improve
depression treatment increase work functioning [12] so
that selected employers can realize a return on invest-
ment (ROI) [13] with competitively priced evidence-
based products [14]. Earlier studies note that employers
report substantial information deficits about the costs
that organizations absorb from employee depression,
and note that they are willing to apply program savings
from improved absenteeism and productivity at work
against program costs [15].
In a study of health benefit professionals representing
293 U.S. employers across the country interested in de-
pression in the workplace, we conducted a randomized
trial to test an intervention which provided employers a
scientifically derived company-specific ROI estimate with
the purchase of a high quality depression product. Pro-
vided by health plans, disease management vendors and
managed behavioral health organizations, depression pro-
ducts provide screening, education, systematic monitor-
ing, and clinician feedback for all interested employees at
an additional cost to the health premium [14]. In the first
randomized controlled trial to our knowledge to be con-
ducted in health benefit professionals, the study hypo-
thesized that employers randomized to the intervention
condition would report more positive depression product
appraisal and greater depression product purchasing be-
havior over 24 months than employers randomized to the
comparison condition.
Methods
Design
To conduct this randomized controlled trial, the research
team modified its previously published design [16] to
invite all National Business Coalition on Health (NBCH)
coalitions and 12 related professional groups in the
United States to participate in the study to recruit the
number of needed subjects. The 29 coalitions/groups
responding to the invitation reviewed eligibility criteria
before inviting interested senior health benefit profes-
sionals (hereafter referred to in this manuscript as em-
ployers) to participate in the study. Eligibility criteria
required that interested employers: (a) represent public or
private companies employing 100 or more non-unionized
employees, (b) their companies intended to remain in the
coalition/group for the next two years, and (c) their com-
panies had not already purchased a depression product for
all its employees. In both the proposed and implemented
design, the study excluded unionized employees because
unions generally negotiate health benefits for their mem-
bers directly with employers. Identified employers were
block randomized by size within coalition at a 1:1 ratio to
one of two conditions between April 2009 and May 2011,
when recruitment was terminated to provide sufficient
time for two year follow-up. Employers in each condition
were invited to participate in an intervention or compa-
rison presentation held in their coalition/group’s geogra-
phic area to learn more about state-of-the-art strategies
employers could utilize to improve depression in the
workplace. Two hundred ninety three of 356 identified
employers (82.3%) met eligibility criteria and attended the
presentation (or webinar at a later date) to which they
had been randomized. Baseline data were collected im-
mediately before employers learned which strategy their
presentation addressed. Follow-up data were collected
immediately after the presentation, at 12 months, and at
24 months (see Figure 1), with the final subject comple-
ting follow-up in July 2013. The protocol and the in-
formed consent that employers signed were approved by
the Institutional Review Boards at Florida State University
and the University of South Florida.
Presentation - Described in detail [16,17], employers
randomized to the intervention condition received an
evidence-based (EB) presentation, while employers ran-
domized to the comparison condition received an en-
hanced usual care (UC) presentation. Based on academic
detailing interventions [18,19], both presentations pre-
sented scientifically-based information on depression in
the workplace. Both presentations were delivered by the
same presenter in separate meetings (e.g., one in the mor-
ning and the other in the afternoon). Email reminders of
key points in the presentation plus encouragement to
request free unbiased technical assistance from the pre-
senter were sent 15-, 17-, and 19-months after the pres-
entation. The presenter (DM) was a former NBCH board
member, who herself directed a regional business coalition
which participated in pilot testing the intervention. The
presenter completed a survey immediately following each
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presentation verifying that presentation components were
delivered according to protocol.
Intervention (EB) Presentation – Piloted and refined
before its implementation, the 25 minute EB presenta-
tion educated employers about high quality depression
care and its evidence-based impact on clinical and work
outcomes [12,20]. Each participant received a company-
specific ROI generated by a calculator that the research
team developed in earlier studies translating scientifically
derived estimates of the impact of high quality depres-
sion care on absenteeism and productivity at work to a
monetized savings in lost work days, varying pertinent
employee, organizational, and vendor characteristics [21].
Employers who did not provide the information needed to
calculate an ROI before the presentation were provided
ROIs by email as soon as they provided the data to the
research team. The presenter explicitly encouraged em-
ployers to explore purchasing a high quality depression
product and offered free unbiased technical assistance.
Comparison (Enhanced UC) Presentation - A similar
length presentation educated employers about Health-
care Effectiveness Data and Information Set (HEDIS) in-
dicators for antidepressant medication management and
their use in monitoring outpatient depression treatment
quality. Employers received HEDIS indicators for anti-
depressant medication management for their most sub-
scribed plan if that plan reported its HEDIS scores to
the National Committee for Quality Assurance (NCQA);
otherwise, employers received HEDIS depression indica-
tors for all plans in the area. During the presentation,
employers were asked to encourage their most subscribed
health plan to improve its HEDIS indicators for depres-
sion (or to calculate its HEDIS indicators if it did not re-
port them) and offered free unbiased technical assistance.
Because previous studies indicate that the information
included in the HEDIS presentation will have little to no
impact on employer health benefit purchasing [22-24],
purchasing behavior in the enhanced UC condition cap-
tures vendor efforts to market depression products to em-
ployers in both conditions during follow-up.
Data collection
Employers completed computerized surveys immediately
before and after the presentation in the presentation
room and at 12 and 24 month follow-up at their home or
office. The research team member who actively contacted
Assessed for eligilility (n=419)
Randomized (n=293)
Allocation
Enrollment
Post-Intervention Follow-Up
Analysis*
12 Month Follow-Up
24 Month Follow-Up
Excluded (n=126)
•   Not meeting inclusion criteria (n=16)
•   Declined to participate (n=63)
•   Ineligible for other reasons (n=47)
Allocated to UC intervention (n=153)
• Received allocated intervention (n=153)
Allocated to EB intervention (n=140)
• Received allocated intervention (n=140)
Lost to follow-up (n=0)
Analyzed (n=124)
Lost to follow-up (n=23)
•   Declined (n=19)
•   Left job with no replacement (n=4)
Lost to follow-up (n=42)
•   Declined (n=34)
•   Left job with no replacement (n=8)
Lost to follow-up (n=0)
Analyzed (n=126)
Lost to follow-up (n=31)
•   Declined (n=25)
•   Left job with no replacement (n=6)
Lost to follow-up (n=49)
•   Declined (n=39)
•   Left job with no replacement (n=10)
*requires completion of 12 and/or 24 month follow-up.
Figure 1 Flow diagram.
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employers who did not respond to an email cue to com-
plete follow-up was blinded to experimental condition.
Employers were paid $100 for completing the pre- and
post-presentation survey, $100 for completing 12-month
follow-up, $100 for completing 24-month follow-up, and
an additional $50 bonus for completing all surveys or for
completing the 24-month follow-up survey if they failed
to complete the 12-month survey. EB and UC employers
were comparably likely to complete 12 and/or 24 month
follow-up (see Figure 1).
Operationalization of major constructs
Depression Product - Each survey defined depression
product as a “depression disease management program
to assure all employees with depression have the oppor-
tunity to get high quality care for the condition by confi-
dentially providing education, monitoring and clinician
feedback. By depression product, we do not mean a dis-
ease management program for chronic illness that adver-
tises it provides care management for depression to the
physically ill employees it serves.”
Depression Product Appraisal - We defined product
appraisal as the ratio between perceived organizational
benefit of a depression product and its relative organi-
zational cost. Higher appraisal values reflect higher ben-
efits at lower costs. Perceived organizational benefit was
measured as the mean of four items (alpha = 0.84) that
employers completed after they read the following vig-
nette. “Imagine that your organization purchased a de-
pression product. By depression product, we mean [insert
definition from above]. The program costs your organiza-
tion $800/year for each participating employee. You know
two other companies who told you they thought that the
product was worthwhile.” The four items are: (a) Would
you expect the product to help depressed worker meet
responsibilities at work over the short term (the first 6
weeks)?; (b) Would you expect the product to help de-
pressed worker meet responsibilities at work over the long
term (the first 6 months)?; (c) Would you expect the prod-
uct to help prevent friction between depressed worker and
his/her coworkers?; (d) Would you expect the product to
help reduce treatment costs that contribute to increase in
health premiums the next year? Response choices were:
(1) no help; (2) little help; (3) moderate help; (4) consider-
able help; (5) great deal of help. Relative organizational
costs was measured by a single item. “Managers often face
the following issues when an organization considers a new
health program. How would you rate the program de-
scribed above?” with reverse-coded response choices being
(1) much worse than programs our organization has re-
cently undertaken; (2) worse than …; (3) better than …;
and (4) much better than programs our organization has
recently undertaken. If an employer reported that a
depression program would provide them little help in
helping workers meet their short term (Question a) and
long term responsibilities (Question b) at work, moderate
help preventing friction between the depressed worker
and his/her coworkers (Question c), and no help reducing
treatment costs (Question d), the numerator of the ratio
would be calculated as 2 + 2 + 3 + 1 = 8. If an employer re-
ported that that a depression program costs were much
better than programs the organization had recently under-
taken, the (reverse coded) denominator would be 2. The
depression product appraisal ratio would be 8/2 = 4.
Depression Product Purchasing Behavior –We mea-
sured purchasing behavior of a depression product over
the previous 12 months by employer self-report using a
four-level ordinal variable: (1) no internal or external dis-
cussion of a depression product and no product pursuit;
(2) internal or external discussion and no product pursuit,
(3) internal and external discussion and no product pur-
suit, and (4) product pursuit. Internal discussion was
defined as an email exchange, telephone call, in-person
meeting or group meeting with other employees of the
company. External discussion was defined as an email ex-
change, telephone call, in–person meeting or group meet-
ing with a vendor. Product pursuit was defined as decision
to purchase a depression product, release of a request for
proposal (RFP) for a depression product, or completion of
a contract with a vendor for a depression product. This
definition of product pursuit captured several employers
who met eligibility criteria for the study because they had
released an RFP but had not completed a contract at
baseline.
Wellness Product Purchasing Behavior – Because the
study was designed to understand health benefit decision-
making, employers were asked to identify other benefits
they pursued in the 24 months following the presentation
by asking employers at 12- and 24-month follow-up “In
your organization, what new health benefits/initiatives
were given priority this year?” Employers who responded
to this open-ended question were allowed to identify more
than one benefit/initiative. A research team member de-
veloped 13 categories (e.g., employee assistance program,
healthy baby program) plus other before coding all re-
sponses to the question at 12-month follow-up [25]. A
second coder used the categories to code all responses to
the question at 24-month follow-up. To measure wellness
product purchasing behavior (yes/no), we identified those
employers who indicated they had prioritized a wellness,
health rewards and/or prevention product (not otherwise
specified) at 12 and/or 24 months. We chose to examine
wellness benefits because our coalition collaborator [DM]
indicated that wellness had become a ‘hot’ topic in benefit
purchasing.
Covariates – We examined the contribution of baseline
measures of organizational characteristics, health benefits
characteristics, employer characteristics, and methods
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characteristics to intervention impact [26,27]. Organiza-
tional characteristics included organizational size, age,
type, number of sites, absenteeism monitoring, presentee-
ism (productivity at work) monitoring, centralized health
benefit decision making, local health benefit decision ma-
king, size of health benefit purchasing group, financial
member in health benefit purchasing group, and NBCH
affiliation. Health benefit characteristics included per-
ceived depression impact, estimated depression prevalence
in workforce, number of health plan carriers, insurance
risk, health benefit generosity (defined in Table 1), any
mental health carveout, any employee assistance program
(EAP), health benefit risk taking (defined in Table 1), re-
sources for new health benefits in the next year, expected
percentage increase in health insurance premiums, politi-
calization of health care benefit decision making (defined
in Table 1), knowledge of vendor who sells depression
products, and company-specific estimate of ROI with a
depression product (provided to EB employers and calcu-
lated for enhanced UC employers). Characteristics of the
employer (e.g., the senior health benefit professional in the
company who provided all data on the company in this
study) included gender, race/ethnicity, age, and report
of his/her influence in company’s health benefit deci-
sion making. Methods characteristics included employer
completion of intervention in group presentation versus
webinar, original employer versus replacement employer
completion of follow-up interview, and intervention
fidelity. Intervention fidelity was defined as presenter
checklist that all components of the presentation had
been completed.
Contamination – Because employers were randomized
within coalitions, it is possible that employers random-
ized to enhanced UC learned about depression products
Table 1 Measurement of key covariates
Construct Coding of items Content of items
Health Benefit Generosity Sum of 11 benefits to which employers
contributed some or all of the costs
Employee Assistance Programs
Return to Work Programs
Chronic Disease Management Programs
Stress Reduction Programs
Smoking Cessation Programs
Obesity Programs
Prenatal or Well Baby Programs
Grief Recovery Programs
Fitness Facilities or Membership
Onsite Site Vaccinations
Health Risk Appraisals
Health Benefit Risk Taking Mean of responses to 5 items coded on
a 4 point Likert scale
1. Our organization’s health benefits philosophy is that in the long run we
get ahead playing it slow, safe and sure (reverse coded).
2. Our organization has built its health benefits program by taking calculated
risks at the right time.
3. Decision-making about health benefits in our company is too cautious for
maximum effectiveness (reverse coded).
4. Health benefits managers in our organization are willing to take a chance
on a good idea.
5. It is necessary to take some pretty big risks occasionally to keep our health
benefits ahead of our competitors.
Politicalization of Health
Benefit Decision-Making
Single item In most organizations, some individuals have more influence than others in
benefit decision-making. For example, one person may make a final decision
without looking for substantial input because s/he is in a position where
people are expected to make final decisions (influence because of position).
Alternatively, one person can influence a final decision because the decision-
maker particularly values his/her opinion (influence because of “who you
know”). During the past 12 months, were differences in influence in benefits
decision-making in your organization due to differences in:
1. position primarily
2. position more than “who you know”
3. “who you know” more than position
4. “who you know” primarily
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from their colleagues in the coalition who were random-
ized to the EB condition. To examine this, the research
team created a variable for enhanced UC subjects only
that indicated the average post-presentation depression
product appraisal value reported by EB colleagues with
whom the UC subject had professional contact with dur-
ing the previous year.
Data analysis
The research team used a linear mixed model to test
intervention impact on appraisal and a longitudinal or-
dinal model to test intervention impact on purchasing
behavior while taking into account the dependence of
observations over time and within coalition. The longi-
tudinal ordinal model tested intervention impact without
assuming a linear effect over time, reflecting that em-
ployers would be expected to report lower purchasing
values at 24-month follow-up if they purchased a de-
pression product at 12-month follow-up. Depression pro-
duct appraisal was log transformed to achieve a normal
distribution before analysis. Covariates that predicted the
dependent variable at p < .20 were included in the final
models testing intervention impact. The research team
analyzed all available data over 24 months (allowing
employers who completed either 12- and/or 24-month
follow-up to remain in the analysis), testing intervention
impact using two-tailed p values. The contamination
analysis used the linear mixed models described above
to examine the impact of EB colleague appraisal ratings
on UC appraisal ratings in enhanced UC subjects only.
Sensitivity analyses of intervention impact on product
appraisal and purchasing behavior were conducted in
employers who completed both follow-ups and analyses
using last value carried forward. Depression product
purchasing behavior at baseline was included as a covar-
iate in the appraisal model and as the first wave of the
dependent variable in the depression product purcha-
sing models. Changes from baseline in appraisal and
purchasing behavior measures were obtained from these
statistical models and compared between EB and en-
hanced UC groups. The 250 employers who completed
either or both follow-ups provided the study 80% power
using two-tailed p values to find a .40 effect size on de-
pression product purchasing behavior with an intraclass
correlation as high as 0.02 introduced by the clustering
of subjects within coalitions. Exploratory analyses were
conducted by examining the frequencies of alternative
benefits that employers prioritized in the two years fol-
lowing the presentation.
Results
Description – Randomization produced EB and enhanced
UC employer groups with statistically comparable or-
ganizational, health, subject and methods characteristics
(see Table 2) in 32 comparisons with the exception
that EB employers were more likely to be racial/ethnic
minorities.
At baseline, EB employers reported a non-transformed
depression product appraisal ratio of 1.56 (SD = 0.65)
while enhanced UC employers reported a 1.46 (SD = 0.48)
ratio. At baseline, EB employers reported a 1.34 (SD =
0.75) depression product purchasing score while enhanced
UC employers reported a 1.48 (SD = 0.87) score.
Depression Product Appraisal – Depression product
appraisal values could be estimated for 232 of the 250
subjects who completed 12 and/or 24 month follow-up,
with 18 subjects eliminated from analysis because of miss-
ing data. The intervention had no impact on depression
product appraisal over 24 months (ES = .03, F = 2.36,
p = .07) in the covariate adjusted model (see Figure 2).
Covariates meeting inclusion criteria for the final ap-
praisal model included gender, previous knowledge of
vendor, absenteeism monitoring, presenteeism monito-
ring, health benefit risk taking, health benefit generosity,
organizational need, and previous depression product pur-
chasing activity. In the final appraisal model, increasing
depression product appraisal over time was independently
predicted by companies whose participants were male
(beta = .08, p = .03) and by greater benefit generosity
(beta = .01, p = 03). Estimated ROI or its interaction with
intervention did not predict change in depression prod-
uct appraisal over time in bivariate analyses and thus
was not included in the final model. Sensitivity analyses in
employers who completed both follow-ups and analyses
using last value carried forward also failed to show signifi-
cant intervention impact.
Depression Product Purchasing Behavior – Depression
product purchasing behavior could be estimated for all
250 subjects who completed follow-up. The intervention
had no impact on depression product purchasing behavior
over 24 months (chisquare = 1.82, p = .44) in the covariate-
adjusted model (see Figure 3). Organizational character-
istics meeting criteria for inclusion in the final model
included organizational size, age, benefit generosity, health
benefit risk taking, absenteeism monitoring, and financial
member in health benefit making decision group. Health
benefit characteristics included politicalization of decision,
insurance risk, EAP, previous knowledge of depression
vendor, mental health carveout and expected benefit pre-
mium increase. Employer covariates included influence on
health benefit decision making in company.
In the final depression product purchasing model,
greater odds of purchasing behavior were independently
predicted by company size (small companies more than
large companies, beta = −0.58, p = .03), previous know-
ledge of a vendor that sold depression products (beta =
1.23, p < .0001), greater health benefit risk-taking (beta =
0.60, p = 0.03), and less politicalization of health care
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Table 2 Baseline characteristics
Overall EB Group Enhanced UC group
(n = 293) (n = 140) (n = 153)
Organizational characteristics
Number of U.S. (SD) sites 23.4 (114.0) 32.6(156.7) 15.0 (47.2)
Size
% small (100 to 500 employees) 34.1 30.7 37.3
% medium (501 to 2500 employees) 30.4 30.0 30.7
% large (2501 plus employees) 35.5 39.3 32.0
Type
% for-profit 57.0 53.6 60.3
% not-for-profit 21.0 23.6 18.5
% public sector 22.0 22.8 21.2
Company age (SD) 75.9 (47.9) 76.8 (50.1) 75.0 (45.0)
% with any absenteeism monitoring 73.2 74.1 72.4
% with any productivity at work monitoring 56.4 53.8 58.7
Mean size of health benefit purchasing group (SD) 7.1 (6.4) 7.2 (6.5) 7.0 (6.4)
% centralized decision making 93.8 95.0 92.8
% local decision making 85.6 89.2 82.3
% purchasing groups with finance representative 80.1 78.5 81.7
% National Business Coalition on Health (NBCH) member 72.7 71.4 73.9
Health benefit characteristics
Mean depression impact (SD) * 2.4 (0.5) 2.5 (0.5) 2.4 (0.5)
% estimating depression prevalence greater than or equal to 11% 51.8 50.8 52.8
Mean number of health plan carriers (SD) 2.2 (2.5) 2.3 (2.9) 2.1 (2.1)
Insurance risk
% fully insured 21.5 23.9 19.3
% self-insured 48.3 46.4 50.0
% mixture of full and self-insured 30.2 29.7 30.7
Health benefit generosity 6.3 (3.0) 6.4 (2.9) 6.2 (3.1)
% with any mental health carveout 18.2 20.8 18.7
% with Employee Assistance Program (EAP) 80.4 80.6 80.3
Mean health benefit risk taking (SD) * 2.3 (0.5) 2.3 (0.5) 2.4 (0.5)
Mean new health benefit resources (SD) * 2.5 (0.7) 2.5 (0.7) 2.6 (0.7)
Mean expected % premium increase (SD) 7.4 (5.2) 7.8 (5.1) 6.9 (5.2)
Mean politicalization of health care benefit decision-making (SD)* 1.6 (0.8) 1.6 (0.8) 1.6 (0.9)
Mean estimated return on investment with depression (SD) 2.5 (2.0) 2.5 (2.1) 2.4 (2.0)
% knowledge of any vendor who sells depression products 50.0 51.8 48.3
% previous pursuit of depression product at baseline (SD) 1.4 (0.8) 1.4 (0.8) 1.5 (0.9)
Employer characteristics
% female 69.8 71.2 67.9
% racial/ethnic minority+ 13.6 17.1 9.2
Median age 41-50 years 41-50 years 41-50 years
% moderate to complete influence over benefit decision-making 74.5 76.4 73.2
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benefit decision making (beta = −0.56, p = .0004). Esti-
mated ROI or its interaction with intervention did not
predict depression product purchasing behavior over time
in the bivariate model and thus was not included in the
final model. Sensitivity analyses in employers who com-
pleted both follow-ups and analyses using last value car-
ried forward also failed to show significant intervention
impact.
Contamination – The contamination variable was not
related to depression product appraisal change over 24
months in enhanced UC employers in bivariate analysis
(F = 1.01, p = .46); thus, multivariate analyses were not
undertaken.
Exploratory Analysis – Two hundred two of the 250
employers completed the open-ended question about
benefits that were given priority at either 12- and/or
24-months, with 41.8% of EB employers reporting that
wellness programs were given priority in their companies
in the previous year compared to 36.5% of enhanced UC
employers (chi square = 0.59, p = .44).
Discussion
This study demonstrated that brief intervention present-
ing scientifically derived company-specific ROI estimates
associated with purchase of a high quality depression
product delivered by a nationally recognized employer
coalition director had no impact on employer appraisal
or purchasing behavior of depression products over two
years. Depression product appraisal was more likely to
increase in companies whose participants were male and
companies with greater benefit generosity. Depression
product purchasing behavior had greater odds of increas-
ing in small companies than large companies, companies
who knew a vendor that sold depression products at base-
line, companies whose cultures supported greater health
benefit risk taking, and companies with less politicaliza-
tion of health care benefit decision making. It is difficult
to compare these findings to previous research because
the research team identified only one other intervention
study currently in progress [28] to influence decision-
making in public health benefit purchasers.
If in fact policy researchers learn more from their
failures than from their successes, this trial produced
hard-won insights. Although it was considerably more
challenging to identify interested coalitions and em-
ployers than our pilot study indicated, the recruit-
ment protocol resulted in bringing influential health
benefit professionals “to the table” with 75% of
Table 2 Baseline characteristics (Continued)
Methods characteristics
% completing presentation in person 84.1 85.0 83.0
% replacement subject completed 12 and/or 24 month follow-up 5.0 7.9 2.2
% presentation fidelity 100 100 100
*Scale of 1–4 with higher scores representing greater amounts of the construct.
+p < .05.
SD = standard deviation.
Figure 2 Intervention impact* on (Log) depression product appraisal.
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employers reporting moderate to complete influence
over health benefit decision-making in their company.
The project explicitly designed its recruitment strategy
to study ‘ready to change’ employers rather than a na-
tionally representative sample to observe non-diluted
intervention impact. Despite the fact that participating
employers initially reported substantial interest in and
capacity to adopt depression products [26], their failure
to request any free and unbiased technical assistance
indicated they were not ‘ready to change’. Participating
employers were however ‘ready to be studied’, as stan-
dard follow-up protocols achieved generalizable follow-up
rates allowing 85% of subjects to remain in longitudinal
analyses. The high follow-up rate is particularly notable
because no other published study has conducted longi-
tudinal research in a national sample of health benefit
decision-makers, providing the country’s first data on
the attitudes and behaviors of employer purchasers and
how they change over time in response to and independ-
ently of intervention. We note that this study does not dir-
ectly inform the field’s understanding of health benefit
decision-making in countries with national health pro-
grams where employers are not direct purchasers of care.
The intervention tested in this trial was modeled after
a presentation piloted in 15 employers in the presenter’s
(DM) coalition, which resulted in 20% of participating em-
ployers pursuing depression products over two years.
Since both the pilot study and the intervention trial pre-
sented similar content to presumably similar employers,
we considered three different explanations for the pilot
study’s success and the intervention trial’s failure to influ-
ence purchasing behavior: (1) historical differences, (2) de-
sign differences, and (3) leadership support differences.
Historical Differences – Because the intervention trial
directly coincided with the initiation of health care reform
which required health benefit professionals to focus their
attention on new federal requirements, it is possible that
health care reform reduced the success of the interven-
tion. While the competing demands of health care reform
increased the study’s difficulty recruiting coalitions and
employers, reform did not completely stall health benefit
decision-making as ~40% of EB employers pursued new
wellness/prevention programs in the two years following
the presentation. With modest scientific evidence of their
ROI on health care expenditures [29], wellness programs
appear to have moved into the employer spotlight that
depression enjoyed in the mid 2000’s when the current
intervention trial was planned. Employer choice to pursue
wellness programs over depression disease management
reflects that employers may be more enthusiastic about
programs which promise to deliver ROI in observable re-
ductions in health care expenditures rather than difficult
to observe improvements in workplace productivity. Em-
ployer choice to pursue wellness programs over depres-
sion disease management may also reflect that employers
prioritize ‘plug and play’ benefits likely to reach the broad-
est number of employees, moving depression and other
mental health conditions far down the list.
The intervention trial also coincided with increasing
employer disillusionment with disease management ini-
tiatives in general [30] as purchasers recognized that
vendors often failed to deliver programs with the prom-
ised reductions on health care expenditures. In retrospect,
the enthusiasm we observed about disease manage-
ment programs in the pilot study had molted to serious
skepticism by the time of the intervention trial. While
Figure 3 Intervention impact* on depression product purchasing behavior.
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disappointing, employer skepticism towards disease man-
agement products is not unfounded. After learning that
only one of 14 depression product vendors sold a product
delivering the four critical components of depression dis-
ease management at the recommended intensity/duration
[14], the research team expanded the intervention to pro-
vide free technical consulting to employers on how to pur-
chase a ‘high quality’ depression disease management
product. Sadly, the one vendor selling a competitively-
priced high quality product discontinued it after three
years for lack of demand.
Design Differences – The pilot study utilized a pre-
post intervention-only design to test the EB presenta-
tion, while the intervention trial randomized employers
to the EB or enhanced UC conditions. While the en-
hanced UC presentation did not provide any information
on depression products and their potential for ROI, the
instruments that both EB and enhanced UC employers
completed pre- and post-presentation provided a de-
tailed description of depression products to ensure that
all participants referred to the same product when rating
it. While the instrumentation may have caused more
similar between-group appraisals than would have other-
wise existed, it is unlikely that the instrumentation influ-
enced enhanced UC employers to purchase depression
products (were it that easy…). A second source of design
error was the potential for content sharing between em-
ployers in the same coalition randomized to opposite
presentations; however, we could observe little evidence
of this. In balance, the decision to randomize within co-
alition to reduce the impact of historical threats ap-
peared to have worked in the study’s favor.
Leadership Support Differences – Another critical dif-
ference between the pilot study and the intervention trial
was the support that the directors of participating coali-
tions/groups provided. In the pilot study, the coalition dir-
ector (DM) presented critical parts of the content to
employers in her coalition, emphasizing to employers who
trusted her that researchers had succeeded in defining the
critical components of a purchasable depression product
to improve workplace outcomes. In the intervention trial,
coalition directors had substantially less involvement,
oftentimes balancing the demands of the study against the
needs of other initiatives the coalition was prioritizing.
Many employers in the intervention trial refused to accept
that scientific estimates of workplace productivity attribut-
able to depression were generalizable to their company,
citing that before they would purchase a depression prod-
uct they would need hard evidence of productivity deficits
in their own workforce [25] rather than accept rigorously
derived national estimates. Other employers questioned
the study’s ‘real’ intention, suspicious that the research
team was working with Accountable Care Act proponents
to ‘sell’ employers on health care reform. To increase
employer’s trust in the science, future intervention sci-
entists may need to design interventions that can be
co-delivered by a nationally recognized experts and
local opinion leaders (e.g., coalition directors or lead-
ing employers in the coalition).
Limitations in the study’s design and implementation
could also have contributed to the study’s negative re-
sults. We selected a single presenter to provide both the
EB and enhanced UC presentations to assure that pre-
senter characteristics did not inadvertently contribute to
the outcomes we observed. In retrospect, we recognize
that our objective fidelity measure could not capture
whether the presenter (DM) was perceived as favoring
one approach to improving depression treatment more
than the other. Further research is needed to investigate
this and other sources of bias in the effective presenta-
tion of evidence-based benefits to employer audiences. It
is also possible that our study measures were not suffi-
ciently sensitive to change, particularly our measure of
depression product appraisal. While measurement in any
new field can no doubt be improved, we do not think in-
strumentation challenges made a major contribution to
this negative trial. Analyses conducted from both a clas-
sical test theory and item response theory approach dem-
onstrated that the organizational benefits construct (the
numerator in depression product appraisal) had encour-
aging psychometric validity [26]. Our initial examination
of this measure showed that it significantly predicted
product pursuit in the pilot trial.
Conclusions
This study contributes to the literature by describing the
disappointing outcomes of the first randomized trial to
encourage health benefit professionals to purchase value-
based health care products with ROI. The intervention
had no observable impact on depression product appraisal
or product purchase over two years. The lackluster em-
ployer response to relevant scientific findings presented in
an easy to understand manner with award-winning graph-
ics documents that the chasm between implementation
science and health benefit decision-makers is huge. Policy
makers will need to build innovative bridges to employers
before these purchasers trust and utilize findings from
implementation science, even when the directions the
science recommends indicate the potential for finan-
cial savings.
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